Physician profile
James Boyer
NPI 1801452073
$633.70
in general payments reported to CMS, 2019-2025
13 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.42 · 2023: $99.32 · 2024: $345 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $618.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $168.78 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $114.67 | 2023-2025 | Rybelsus, Ozempic |
| Amgen INC. | $72.64 | 2023-2024 | Repatha, Evenity, Prolia |
| Inspire Medical Systems, INC. | $49.58 | 2024 | Inspire |
| Pfizer INC. | $45.15 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $41.32 | 2024 | |
| Lilly USA, LLC | $32.42 | 2023-2024 | Mounjaro |
| Merck Sharp & Dohme LLC | $22.52 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $20.00 | 2024 | Spravato |
| Csl Behring | $19.25 | 2025 | Hizentra |
| Glaxosmithkline, LLC. | $16.75 | 2024 | Arexvy, Shingrix |
| Stryker Corporation | $15.42 | 2022 | |
| Currax Pharmaceuticals LLC | $15.20 | 2024 | Onzetra Xsail, Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Boyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.